4.4 Review

Dysregulation of microRNA biogenesis machinery in cancer

Journal

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/10409238.2015.1117054

Keywords

Argonaute; DGCR8; Dicer; Drosha; microRNA; post-translational modifications; pre-miRNA; pri-miRNA; processing; stability; TRBP

Funding

  1. LeDucq Transatlantic Network of Excellence in Cardiovascular Research Program
  2. National Institutes of Health (NIH) [HL108317, HL116191]
  3. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL116191, R01HL108317] Funding Source: NIH RePORTER

Ask authors/readers for more resources

MicroRNAs (miRNAs) are integral to the gene regulatory network. A single miRNA is capable of controlling the expression of hundreds of protein coding genes and modulate a wide spectrum of biological functions, such as proliferation, differentiation, stress responses, DNA repair, cell adhesion, motility, inflammation, cell survival, senescence and apoptosis, all of which are fundamental to tumorigenesis. Overexpression, genetic amplification, and gain-of-function mutation of oncogenic miRNAs (onco-miRs) as well as genetic deletion and loss-of-function mutation of tumor suppressor miRNAs (suppressor-miRs) are linked to human cancer. In addition to the dysregulation of a specific onco-miR or suppressor-miRs, changes in global miRNA levels resulting from a defective miRNA biogenesis pathway play a role in tumorigenesis. The function of individual onco-miRs and suppressor-miRs and their target genes in cancer has been described in many different articles elsewhere. In this review, we primarily focus on the recent development regarding the dysregulation of the miRNA biogenesis pathway and its contribution to cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available